Efficacy and tolerability of botulinum toxin type a in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: Comparison of two doses

European Urology

Volumn 58, Issue 5, 2010, Pages 759-766

  Grise, Philippe ^a   Ruffion, Alain ^b   Denys, Pierre ^c   Egon, Guy ^d   Chartier Kastler, Emmanuel ^e  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b Hospices Civils ^*  (France)

^c Garches University Hospital   (France)

^d Centre de l'Arche   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Botulinum toxin type A; Cholinergic antagonist; Detrusor overactivity; Neurogenic; Urinary incontinence; Urodynamics

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETRUSOR MUSCLE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INJECTION; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SPINAL CORD INJURY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; URODYNAMICS;

ADULT; BOTULINUM TOXINS, TYPE A; CHOLINERGIC ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 77957552125     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.06.035     Document Type: Article

References (21)

1. C.R. Chapple, V. Khullar, and Z. Gabriel The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol 54 2008 543 562
2. A. Giannantoni, S.M. Di Stasi, and R.L. Stephen Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study J Urol 172 2004 240 243
3. B. Schurch, M. de Sze, and P. Denys Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study J Urol 174 2005 196 200
4. I. Ehren, D. Volz, and E. Farrelly Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study Scand J Urol Nephrol 41 2007 335 340
5. G. Del Popolo, M.T. Filocamo, and V. Li Marzi Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre Eur Urol 53 2008 1013 1020
6. A. Ruffion, O. Capelle, and P. Paparel What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97 2006 1030 1034
7. S. Hori, P. Patki, and K.H. Attar Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury BJU Int 104 2009 216 220
8. M. Stoehrer, A. Wolff, and G. Kramer Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years Urol Int 83 2009 379 385
9. I.F. Ghalayini, M.A. Al-Ghazo, and Z.A. Elnasser Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity Int Urol Nephrol 41 2009 805 813
10. A.K. Patel, J.M. Patterson, and C.R. Chapple Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results Eur Urol 50 2006 684 710
11. ®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review Eur Urol 53 2008 275 287
12. A. Apostolidis, P. Dasgupta, and P. Denys Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report Eur Urol 55 2009 100 120
13. K. De Laet, and J.J. Wyndaele Adverse events after botulinum A toxin injection for neurogenic voiding disorders Spinal Cord 43 2005 397 399
14. J. Klaphajone, W. Kitisomprayoonkul, and S. Sriplakit Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions Arch Phys Med Rehabil 86 2005 2114 2118
15. H. Schulte-Baukloh, J. Schobert, and T. Stolze Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis Neurourol Urodyn 25 2006 110 115
16. H.C. Kuo Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions Urology 67 2006 232 236
17. P. Costa, B. Perrouin-Verbe, and A. Colvez Quality of life in spinal cord injury patients with urinary difficulties: development and validation of Qualiveen Eur Urol 39 2001 107 113
18. J. Grosse, G. Kramer, and M. Stöhrer Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence Eur Urol 47 2005 653 659
19. G. Karsenty, A. Reitz, G. Lindemann, S. Boy, and B. Schurch Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity Urology 68 2006 1193 1197
20. A. Giannantoni, E. Mearini, M. Del Zingaro, and M. Porena Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results Eur Urol 55 2009 705 712
21. A. Reitz, P. Denys, and C. Fermanian Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity Eur Urol 52 2007 1729 1735